Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ Scribed by A. Llombart; Galán; C. Fuster; E. Buch; V. Carañana; A. Rodriguez-Lescure; C. Vázquez; A. Guerrero; A. Ruiz; V. Guillam-Porta

• Book ID: 118624661
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 131 KB
• Volume: 4
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(06)80382-4